Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a ...

Point-of-care testing is disrupting global diagnostics, creating opportunities for companies such as Lumos Diagnostics ...

SkylineDX’s test stratifies cutaneous melanoma patients into metastatic risk categories to inform treatment decisions.

Survey of 137 German hospital IT leaders, clinical executives and provider stakeholders finds national patient-record success ...

Northwestern Medicine scientists have demonstrated that a highly sensitive blood test can detect traces of pancreatic cancer ...

The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

Jersey has been chosen to run a clinical medical trial to test new technology it is hoped will lead to improved patient care.

A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

Apollo Cancer Centres launches Shield™ Multi-Cancer Detection, a blood-based test that can detect signs of multiple cancers ...

Few issues have brought Robert F. Kennedy Jr. much cross-party goodwill on Capitol Hill, but his effort to phase out the use ...

Large language models (LLMs) are rapidly being integrated into clinical workflows, supporting tasks such as diagnosis ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment response ...